One of the earliest initiatives launched under the newly established “Make America Healthy Again” platform — spearheaded by Robert F. Kennedy Jr., now Secretary of Health and Human Services — targets a growing and urgent concern: the rising tide of chronic illness among children in the United States.
President Donald Trump recently signed an executive order aimed at confronting what the White House described as a “public health crisis” affecting over 30 million children in 2022 alone. The directive cites alarming statistics: one in 36 children is now diagnosed with autism spectrum disorder, a dramatic increase from estimates of 1 in 10,000 during the 1980s. Nearly one-fifth of adolescents are living with fatty liver disease, about 30 percent are prediabetic, and more than 40 percent are overweight or obese.
According to the administration, some of these conditions may be linked to factors such as poor diet, environmental exposures, and an over-reliance on medications — including those prescribed for mental health and behavioral disorders.
As MedPage Today reported, RFK Jr. has pledged to examine these possible causes without ideological boundaries. “We will convene representatives of all viewpoints to study the causes for the drastic rise in chronic disease,” he said. “Some of the possible factors we will investigate were formerly taboo or insufficiently scrutinized — the childhood vaccine schedule; electromagnetic radiation; glyphosate; other pesticides; ultra-processed foods… SSRIs and other psychiatric drugs; PFAS; PFOA; microplastics — nothing is going to be off-limits.”
In an address to HHS employees, Kennedy emphasized the need for integrity and consensus in research. “Let’s use protocols that we all agree on in advance and not alter the outcomes of studies halfway through because they look inconvenient,” he said. “Let’s all depoliticize these issues and reestablish a common ground for action, and renew the search for existential truths with no political impediments and no preconceptions.”
The executive order calls for a sweeping review of current health strategies and a reorientation of federal health policy. A newly formed MAHA Commission — made up of representatives from agencies such as the FDA, NIH, and CDC — is tasked with developing a broad framework to address chronic childhood illness. This includes re-evaluating national approaches to nutrition, physical activity, medication use, lifestyle choices, technology habits, environmental contaminants, and the overall quality and safety of food and pharmaceuticals.
A key goal of the commission is to increase transparency around existing data and protect scientific recommendations from “inappropriate influence.” The order also mandates a critical review of prescribing trends for medications such as selective serotonin reuptake inhibitors (SSRIs), antipsychotics, stimulants, and weight-loss drugs.
However, the initiative has drawn some criticism, particularly from medical professionals who caution against federal overreach. Dr. Lelach Rave, interim executive director of the Washington Chapter of the American Academy of Pediatrics, expressed concern that the new policies could undermine the doctor-patient relationship.
“Any parent who has a child who is struggling with depression or anxiety or psychosis, it’s a scary place to be,” Rave told The Seattle Times. “Not that you discount the risks of medications because they’re real as well, but there is real risk with disease.”
While Rave agrees that monitoring prescription practices is prudent, she and others warn that a rigid, top-down approach could lead to unnecessary delays or denials in treatment for children in need.
The MAHA Commission is expected to release an initial report within 100 days of the order’s signing. This report will include a nationwide assessment of prescription trends and the potential risks posed by psychiatric medications and weight-loss drugs in children and adolescents.
As the debate unfolds, the administration maintains that its objective is not to restrict access to care, but to promote better health outcomes by identifying root causes and fostering informed, science-based solutions. Whether the initiative will strike the right balance between oversight and access remains a central question in the weeks ahead.
